ARA-290

A non-hematopoietic EPO derivative that provides potent tissue protection and pain relief, particularly for small fiber neuropathy, without increasing red blood cells.

ARA-290

ARA-290

A non-hematopoietic EPO derivative that provides potent tissue protection and pain relief, particularly for small fiber neuropathy, without increasing red blood cells.

  • Starting at $449
Order ARA-290

What Is ARA-290?

ARA-290 is a synthetic peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without stimulating red blood cell production. It has been studied for its potential neuroprotective, anti-inflammatory, and tissue-repair properties.

  • Targets the innate repair receptor (IRR) for tissue protection.
  • May reduce chronic inflammation and promote cellular repair.
  • Does not induce erythropoiesis like traditional EPO.

Who Can Benefit from ARA-290?

ARA-290 is investigational and not FDA-approved for any condition.

  • Chronic inflammation and autoimmune conditions
  • Potential metabolic and tissue repair applications
  • Preclinical studies suggest cardiovascular and renal support

OUR CLIENTS LOVE US - SEE WHAT THEY'RE SAYING

Frequently Asked Questions –
Your Concierge Healthcare, Simplified

No. Unlike full erythropoietin, ARA-290 selectively targets tissue repair pathways without stimulating erythropoiesis.

No. It is considered investigational and is not approved for any medical treatment.

No. Any investigational use should complement standard medical oversight and not replace established treatments.

Studies have explored neuropathic pain, chronic inflammation, metabolic support, and tissue repair. Human data is limited and primarily early-phase or preclinical.